DV
Dividend Vision

TPST — Tempest Therapeutics Inc

Tempest Therapeutics Inc (TPST)

Total return is -100.0% over the past 13.8 years, 712.0 points behind SPY at 612.0%. Its deepest 1-year drawdown was 92.8%.

Tempest Therapeutics is a clinical-stage biotechnology company developing small molecule cancer treatments, with lead candidates including Amezalpat for hepatocellular carcinoma and TPST-1495 for various cancers in collaboration with Roche. The company does not currently distribute dividends. Tempest appeals to investors seeking exposure to early-stage oncology drug development with higher risk and potential for significant upside if clinical trials succeed.

TPST key facts

Asset type
Stock
Asset class
Equity
Inception date
11/12/2012
Last close
$1.01
Market cap
$15,822,813
Average volume
428300.0
Payment date
12/10/2018
Beta
-1.707
Payout ratio
0.0
Forward P/E
0.0
EPS
$-5.98